SCHEMBL20578

SCHEMBL20578

Nc1nc2c(ncn2Cl)c(=O)[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 8/20 0.58
PNP P00491 4/20 0.57
TK1 P04183 2/20 0.54
BLM P54132 2/20 0.52
USP2 O75604 1/20 0.52
TSHR P16473 1/20 0.52
EDNRA P25101 1/20 0.52
HTR2A P28223 1/20 0.52
RECQL P46063 1/20 0.52
HBB P68871 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
CYP3A4 P08684 1/20 0.50
NFKB1 P19838 1/20 0.50
VCP P55072 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HIF1A Q16665 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL986800 0.82 XDH (0.60) XDHPNPTK1BLMUSP2
SCHEMBL41787 0.81 XDH (0.59) XDHPNPTK1BLMUSP2
SCHEMBL27667185 0.81 XDH (0.63) XDHPNPTK1BLMUSP2
SCHEMBL15005119 0.81 XDH (0.59) XDHPNPTK1BLMUSP2
SCHEMBL10835122 0.79 XDH (0.61) XDHPNPTK1BLMUSP2
SCHEMBL8886034 0.79 XDH (0.58) XDHPNPTK1BLMUSP2
SCHEMBL2983847 0.79 XDH (0.57) XDHPNPTK1BLMUSP2
SCHEMBL22533906 0.79 XDH (0.57) XDHPNPTK1BLMUSP2
SCHEMBL2051364 0.79 XDH (0.57) XDHPNPTK1BLMUSP2
SCHEMBL1843776 0.79 XDH (0.57) XDHPNPTK1BLMUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630867-B2 Devices for CRISPR effector system based diagnostics THE BROAD INSTITUTE, INC. (US) 2026-05-19 US disclosed
US-20250243471-A1 PROGRAMMABLE PATTERN RECOGNITION COMPOSITIONS BROAD INST INC (US) 2025-07-31 US disclosed
US-20250223580-A1 PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS THE BROAD INSTITUTE, INC. 2025-07-10 US disclosed
US-20250129355-A1 PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS NATIONAL INSTITUTES OF HEALTH 2025-04-24 US disclosed
US-20250075268-A1 CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-03-06 US disclosed
US-12203145-B2 CRISPR effector system based diagnostics for virus detection THE BROAD INSTITUTE, INC. (US) 2025-01-21 US disclosed
EP-4119663-B1 CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS BROAD INST INC (US) 2024-11-27 EP disclosed
CN-111448311-B Diagnostic system based on multiple effector CRISPR 博德研究所 2024-11-19 CN disclosed
CN-111108220-B Diagnostic based on CRISPR effect system for virus detection 博德研究所 2024-11-19 CN disclosed
US-20240352454-A1 MULTI-EFFECTOR CRISPR BASED DIAGNOSTIC SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2024-10-24 US disclosed
US-20040127454-A1 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases RESPROTECT GMBH (DE) 2004-07-01 US disclosed
WO-2004029064-A1 (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF LG LIFE SCIENCES LTD. (KR) 2004-04-08 WO disclosed
EP-1334109-A2 IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES Santaris Pharma A/S (DK) 2003-08-13 EP disclosed
US-20020086998-A1 Synthesis of purine locked nucleic acid analogues SANTARIS PHARMA A/S (DK) 2002-07-04 US disclosed
WO-2002028875-A2 IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES CUREON A/S (DK) 2002-04-11 WO disclosed
WO-2002024323-A2 HIGH DENSITY MOLECULAR ARRAYS ON POROUS SURFACES PICOLITER INC. (US) 2002-03-28 WO disclosed
EP-0824536-B1 ANTIMALARIAL ORGANOMETALLIC IRON COMPLEXES UNIV LILLE SCIENCES TECH (FR) 2001-08-22 EP disclosed
US-5639440-A ADMINISTERING MIXTURE OF POLYPEPTIDE AND IMMUNOGEN TO TRANSGENIC MAMMAL HAVING TOLERANCE FOR POLYPEPTIDE YIELDS ANTIBODY CAPABLE OF BINDING IMMUNOGEN MARTIN JR DAVID W (US) 1997-06-17 US disclosed
EP-0338168-A1 Phosphonoalkylpurine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1989-10-25 EP disclosed
US-4508898-A Antiviral triazine compounds SYNTEX (U.S.A.) INC. 1985-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086998-A1 Synthesis of purine locked nucleic acid analogues RNGTT, PNP, UNG XDH 598/4885PNP 2/4885TK1 246/4885
US-20040127454-A1 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases PNP, TYMP, ENTPD5 XDH 219/4885PNP 1/4885TK1 24/4885
US-12630867-B2 Devices for CRISPR effector system based diagnostics ZFR, MTREX, ADAR XDH 2266/4885PNP 2592/4885TK1 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.